Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Accumulated Expenses: 2009-2017

Historic Accumulated Expenses for Northwest Biotherapeutics (NWBO) over the last 8 years, with Mar 2017 value amounting to $933,000.

  • Northwest Biotherapeutics' Accumulated Expenses fell 21.53% to $933,000 in Q1 2017 from the same period last year, while for Mar 2017 it was $933,000, marking a year-over-year decrease of 21.53%. This contributed to the annual value of $901,000 for FY2016, which is 31.17% down from last year.
  • As of Q1 2017, Northwest Biotherapeutics' Accumulated Expenses stood at $933,000, which was up 3.55% from $901,000 recorded in Q4 2016.
  • In the past 5 years, Northwest Biotherapeutics' Accumulated Expenses ranged from a high of $1.3 million in Q2 2016 and a low of $655,000 during Q2 2014.
  • For the 3-year period, Northwest Biotherapeutics' Accumulated Expenses averaged around $1.1 million, with its median value being $1.2 million (2015).
  • Per our database at Business Quant, Northwest Biotherapeutics' Accumulated Expenses crashed by 85.71% in 2013 and then soared by 81.37% in 2015.
  • Northwest Biotherapeutics' Accumulated Expenses (Quarterly) stood at $842,000 in 2013, then surged by 43.82% to $1.2 million in 2014, then rose by 8.09% to $1.3 million in 2015, then slumped by 31.17% to $901,000 in 2016, then decreased by 21.53% to $933,000 in 2017.
  • Its last three reported values are $933,000 in Q1 2017, $901,000 for Q4 2016, and $1.3 million during Q3 2016.